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Background: Screening of stable outpatients for CYP2C19*2 is not recommended, in part because the best treatment strategy in these patients is 
unknown. The 2C19*17 allele is associated with increased clopidogrel metabolism and possibly increased bleeding risk. 
Methods: We identified 211 stable outpatients with a history of PCI who were receiving chronic aspirin and clopidogrel therapy and assayed 
CYP2C19 alleles and platelet function (using VerifyNow P2Y12 platelet reactivity units (PRU)). Patients with at least one CYP2C19*2 allele were 
enrolled in a cross-over study comparing 30 days of standard dose clopidogrel (75 mg) to 30 days of high dose clopidogrel (150 mg). In these 
patients, platelet function was further assessed using light transmission aggregometry (LTA) and active clopidogrel metabolites were measured. 
Results: Baseline PRU values while patients were receiving chronic therapy with 75 mg daily of clopidogrel were elevated among CYP2C19*2 
carriers (n=52, 25%) compared to *1*1 wild-type (237.5 vs. 172.0 PRU, p<0.001). Carriers of the 2C19*17 allele (n=51, 24%) displayed similar 
levels of platelet inhibition compared to wild-type patients (166.7 vs. 172.0 PRU, p>0.5). 50 patients with at least one CYP2C19*2 allele completed 
the cross-over study. Treatment with 150 mg daily of clopidogrel was associated with improved ADP-specific platelet inhibition measured by 
VerifyNow (217 vs. 258 PRU, p=0.01) and LTA assessment (51.5% vs. 66.6% of maximal aggregation, p=0.02) compared to 75 mg daily. Both 
VerifyNow and LTA correlated poorly with measured clopidogrel metabolite levels (adjusted r-squared values of 0.27 and 0.23). 
Conclusions: Carriers of CYP 2C19*2 displayed increased platelet reactivity compared to non-carriers as measured by VerifyNow. 2C19*17 carrier 
status did not effect platelet function. Treatment with 150 mg daily of clopidogrel reduced, but did not eliminate, the increased platelet reactivity 
seen in 2C19*2 carriers. LTA and VerifyNow P2Y12 correlated poorly with measured active metabolite levels.
